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A B S T R A C T
GABAA receptor modulating steroid antagonists (GAMSA) selectively inhibit neurosteroid-mediated
enhancement of GABA-evoked currents at the GABAA receptor. 3a-hydroxy-neurosteroids, notably
allopregnanolone and tetrahydrodeoxycorticosterone (THDOC), potentiate GABAA receptor-mediated
currents. On the contrary, various 3b-hydroxy-steroids antagonize this positive neurosteroid-mediated
modulation. Importantly, GAMSAs are speciﬁc antagonists of the positive neurosteroid-modulation of
the receptor and do not inhibit GABA-evoked currents.
Allopregnanolone and THDOC have both negative and positive actions. Allopregnanolone can impair
encoding/consolidation and retrieval of memories. Chronic administration of a physiological
allopregnanolone concentration reduces cognition in mice models of Alzheimer’s disease. In humans
an allopregnanolone challenge impairs episodic memory and in hepatic encephalopathy cognitive
deﬁcits are accompanied by increased brain ammonia and allopregnanolone. Hippocampal slices react in
vitro to ammonia by allopregnanolone synthesis in CA1 neurons, which blocks long-term potentiation
(LTP). Thus, allopregnanolone may impair learning and memory by interfering with hippocampal LTP.
Contrary, pharmacological treatment with allopregnanolone can promote neurogenesis and positively
inﬂuence learning and memory of trace eye-blink conditioning in mice.
In rat the GAMSA UC1011 inhibits an allopregnanolone-induced learning impairment and the GAMSA
GR3027 restores learning and motor coordination in rats with hepatic encephalopathy. In addition, the
GAMSA isoallopregnanolone antagonizes allopregnanolone-induced anesthesia in rats, and in humans it
antagonizes allopregnanolone-induced sedation and reductions in saccadic eye velocity. 17PA is also an
effective GAMSA in vivo, as it antagonizes allopregnanolone-induced anesthesia and spinal analgesia in
rats. In vitro the allopregnanolone/THDOC-increased GABA-mediated GABAA receptor activity is
antagonized by isoallopregnanolone, UC1011, GR3027 and 17PA, while the effect of GABA itself is not
affected.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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GABA is the major inhibitory neurotransmitter within the
central nervous system. It exerts effects by activation of neuronal
membrane-bound GABAA receptors, thereby opening the receptor
chloride channel and in mature neurons chloride usually ﬂows into
the neuron and hyperpolarizes the cell, thereby reducing
excitability. Endogenous steroids, including allopregnanolone
(3a-hydroxy-5a-pregnan-20-one) and THDOC (3a,5a-tetrahy-
drodeoxycorticosterone) are positive allosteric GABAA receptor
modulators [45],Fig. 1. They both act via the same two speciﬁc
binding sites on the receptor [32,31], thereby increasing the
inhibitory tone. Allopregnanolone is formed from progesterone,
and THDOC from deoxycorticosterone, via reactions catalyzed by
5a-reductase followed by 3a-hydroxysteroid dehydrogenase,
which are both present in the brain [47]. Under some conditions,
e.g. stress, at least allopregnanolone is synthesized locally within
the brain [54].
In hippocampal neurons allopregnanolone increases both the
peak amplitude and duration of chloride currents induced by GABA
[45]. While in acutely isolated neurons from the medial preoptic
nucleus allopregnanolone dramatically prolongs the GABA-medi-
ated spontaneous postsynaptic current (sIPSC), probably by
reducing rates of GABA unbinding from the receptor [29]. In such
preparations allopregnanolone also seems to have presynaptic
effects, increasing the frequency of spontaneous GABA release and
thereby increasing the frequency of sIPSCs [30].
THDOC also increases the GABAergic tone by increasing
membrane expression of the a4 GABAA receptor subunit [1]. InFig. 1. Structures of the endogenous GABAA receptor positive allosteric modulators
allopregnanolone and THDOC and the GAMSA isoallopregnanolone.this study it was shown that THDOC potentiates the protein kinase
C-dependent phosphorylation of S443 within the a4 subunit, and
in parallel enhances the insertion of receptors with this subunit
into the membrane. The cell surface levels of receptors with a1 or
a5 subunits where not increased. THDOC by this mechanism
selectively increases tonic inhibition as a4-GABAA receptors are
located extrasynaptically.
2. Learning and memory impairments by allopregnanolone and
THDOC
2.1. Morris water maze tests of rats
The spatial version of the Morris water maze test is used to
study hippocampal-dependent learning and acquisition of long-
term spatial memory in rodents. Acute administration of
allopregnanolone just before testing abolishes rats’ capacity to
learn the position of the hidden platform [36,65], Fig. 2. In the
study by [36] control rats treated with vehicle quickly learned to
complete the task, signiﬁcantly improving during the ﬁrst days and
then maintaining a mean latency to the platform of around 40 s. In
contrast, the latency of rats treated with allopregnanolone
declined very little, remaining longer than 90 s on the sixth day
of learning. This indicates that the rats did not learn the position of
the platform, but occasionally found it by chance, thereby reducing
the mean latency from the maximal 120 s per swim trail. The dose
of allopregnanolone used to affect learning this profoundly was
pharmacological (i.e. 2 mg/kg i.v.), and there was a high brain
allopregnanolone concentration during the swim trials with a
hippocampal concentration of 2 mmol/kg at the start of the
learning session.
Retrieval of memory of the platform’s position is also affected
by acute administration of allopregnanolone. This has been
demonstrated by studies in which rats learnt the platform position
during four or six days in trials without allopregnanolone
treatment. Rats subsequently treated with allopregnanolone, s.c.
17 mg/kg or 20 mg/kg, used a longer path than controls to swim to
the platform [46,20]. However, in a non-spatial version of the test
memory retrieval was not affected in the allopregnanolone-treated
rats and the concentration of allopregnanolone was not reported
[46].
THDOC also impairs rodent learning (5 mg/kg i.p., exposure not
reported), as demonstrated by rats’ performance in the Morris
water maze using a matching-to-place paradigm [58]. The cited
study showed that THDOC disrupts concept learning, working
memory, and reference memory in rats selectively bred to be
seizure-resistant. Interestingly, it also showed that THDOC
administration marginally improved learning and memory in
seizure-prone rats, which normally learn less well. These rats are
known to express different GABAA receptor subunits in some brain
areas [52], which may be involved in the different cognitive effects
of THDOC.
1 2 3 4 5 6
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
A llo p re g n a n o lo n e
V e h ic le
T r ia l d a y
L
a
te
n
c
y
(s
)
A llo :U C 1 0 1 1
*
*
* *
Fig. 2. The GAMSA UC1011 inhibits the impairment of learning in the Morris water maze test induced by allopregnanolone in rats, as manifested by the times rats took to
swim to the platform (latency) after daily injections of 2 mg/kg allopregnanolone, 2 mg/kg allopregnanolone and 20 mg/kg UC1011, or vehicle—10% (2-hydroxypropyl)-
b-cyclodextrin—eight minutes before the start of swimming.
(adapted from Turkmen et al., 2007)
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More than 15 years ago, Reddy and Kulkarni showed that
allopregnanolone (0.25 mg/kg s.c.) impairs rats’ performance in
the plus-maze learning task (the time a test animal spends moving
from the end of one of the open arms to a “safe” covered arm in an
elevated maze) [56]. Rapid completion requires use of spatial long-
term memory, but may also be promoted by anxiety induced by
heights and open spaces. Similarly to benzodiazepines, allopreg-
nanolone has anxiolytic effects [57], thus reductions in anxiety
may contribute to allopregnanolone-treated rats’ slowness in
reaching the “safety” offered by the closed arm. Allopregnanolone
(10 mg/kg i.p.) also disrupts hippocampus-dependent contextual
learning in C57BL/6J mice [22]. This study involved pre-exposure to
a conditioning chamber to speciﬁcally target the focal process
without interfering with pain sensitivity or behavioral perfor-
mance.
Recently, it was shown that allopregnanolone apparently
impairs both encoding and consolidation of an object memory
[55]. First they administered allopregnanolone to male C57BL/6J
mice i.p. either before or immediately after the ﬁrst exploratory
session of a novel object recognition task. Treatment with
allopregnanolone 10 mg/kg or higher at either time point resulted
in no discrimination of the novel object in the test situation 24 h
later, i.e. mice did not remember the familiar object. Further
studies showed that when allopregnanolone (0.1 mg/side) was
micro infused bilaterally into the CA1 region of the dorsal
hippocampus immediately following the object exploratory
session the consolidation of the object memory was similarly
impaired. Systemic allopregnanolone (10 mg/kg i.p.) also impaired
encoding of a contextual memory when administered prior to the
ﬁrst session in the context test. The settings of these tests were
non-spatial, hence allopregnanolone inhibited the formation and/
or storage of non-spatial memory via effects on hippocampal
neurons.
Chronic allopregnanolone administration with continuous
exposure from an s.c. implanted Alzet1 osmotic pump also affects
learning and memory in mice models of Alzheimer’s disease (AD)
[10,9]. Results of cognitive tests reported in these studies indicate
that such exposure advances development of Alzheimer’s signs,
increased levels of soluble beta-amyloid and impaired cognition, inthe mice. In this setting the hippocampal allopregnanolone
concentration was approximately 15 nmol/kg, a physiological
concentration close to that found in rats after acute stress [54].
In sharp contrast, intermittent weekly treatment of AD mice
with a pharmacological allopregnanolone dose induces neuro-
genesis through excitation of neural progenitor cells, thereby
promoting neural proliferation and reducing AD pathology [33],
this is further discussed below. In contrast to mature neurons,
allopregnanolone-induced activation of the GABAA receptor
complex in neural stem cells leads to depolarization.
2.3. Cognition in humans
Allopregnanolone exposure also affects memory in humans
[38]. These authors gave single doses of allopregnanolone
(0.07 mg/kg i.v., 100 nM in plasma) to women, who participated
in memory tests pre- and post- injection. In this setting episodic
memory (verbal recall) was impaired by the substance, relative to
both their pre-injection performance and when vehicle treatment
was received. However, their working memory and semantic
memory were not affected.
There are also indications that allopregnanolone is involved in
hepatic encephalopathy (HE), a debilitating cognitive and psychi-
atric condition caused by decreased liver function. Cognitive
impairment in these patients decreases their quality of life and
affects their daily living [51,8]. More speciﬁcally even early in the
disease’s progression spatial working memory is hampered [41]
and both the learning capacity and short-term memory are
impaired [70]. In addition, low grade HE associated with cognitive
impairment and diagnosed by abnormal electroencephalography
(EEG) and psychometric testing predicts the development of more
severe episodic HE [50]. There is a substantial body of evidence to
suggest that neurosteroids and increased GABAergic tone are
central to the neuropathology in HE [2]. In a landmark study by
Ahboucha et al. [3,4] elevated allopregnanolone concentrations in
the brain (frontal cortex, the only brain region analyzed) of
cirrhotic patients with HE that died in coma was shown, relative to
both cirrhotic patients without HE and controls with neither liver
disease nor psychiatric disorder [4]. Thus, increased levels of
allopregnanolone in the brain were exclusively detected in the
patients with HE. The mitochondrial translocator protein (TSPO) is
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binding sites are up-regulated in both human and experimental HE
[2]. Even in living cirrhotic patients with mild-to-moderate HE
binding of the TSPO ligand [11C] (R)-PK11195 is increased in the
brain [17]. However, no causal link between cognitive impairments
in HE patients and increases in allopregnanolone levels in the brain
has been established, as yet at least, while in rat models of HE/
hyperammonemia increases in GABAergic activity are known to be
involved in the cognitive function [18,27]. More importantly,
recently a GAMSA was shown to improve cognitive and motor
functions in two rat models of HE (see below [37]). Increased brain
ammonia and neuroinﬂammation are also involved in the
development of the neuronal dysfunction in HE [24].
This review focuses on negative consequences of neurosteroids
that are positive modulators of the GABAA receptor and the
possibility to block these negative effects with GAMSA. However,
not all studies show that allopregnanolone negatively affects
cognition, and similarly for progesterone that is the precursor of
allopregnanolone. In a recent review concerning effects of steroids
on learning and memory it was concluded that delivery of
progesterone to women seldom inﬂuence cognitive performance
positively and more often negatively [21]. We also believe that
cognitive dysfunctions caused by allopregnanolone are a concern
that possibly can be prevented by the use of GAMSA.
2.4. Long term potentiation can be inhibited by allopregnanolone
There are several indications that allopregnanolone might
interfere with memory formation by inhibiting long-term poten-
tiation (LTP) [64,35], a form of synaptic plasticity associated with
memory processing. Notably, its synthesis in CA1 hippocampal
neurons contributes to inhibition of LTP formation at certain
conditions. Thus, application of either ethanol or ammonia to rat
hippocampal slices both induces allopregnanolone formation in
CA1 neurons and blocks LTP, and when 5a-reductase is inhibited
with ﬁnasteride the allopregnanolone synthesis is blocked and LTP
can be induced in the presence of ammonia [64,35]. The antibody
used to detect neurosteroids in these studies are speciﬁc for 3a-
hydroxy steroids, and predominantly binds to allopregnanolone,
but other 3a-hydroxy steroids might also be recognized [53]. In
hepatic encephalopathy the concentrations of ammonia and
allopregnanolone are increased in the brain, which may block
LTP and hence memory processes. Interestingly, ﬁnasteride
improves motor-, EEG, and cellular changes in a rat model of HE
and prevents the development of hepatic coma [49].Isoallopregnanolon
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Fig. 3. The GAMSA isoallopregnanolone decreases the allopregnanolone-prolonged sIPS
shown are from one acutely isolated medial preoptic rat neuron. (A) Traces under control
antagonism of the sIPSC when allopregnanolone has not been applied, (B) Allopregnano
allopregnanolone-induced prolongation of the sIPSC.
(adopted from Strömberg et al., 2006)3. Pharmacological allopregnanolone treatments
Contrary to the studies described above treatment with
allopregnanolone can be advantageous for speciﬁc cognitive
performance and can induce neurogenesis and cell survival. In a
series of experiments it has been shown that pharmacologic
allopregnanolone treatment of the triple transgenic mouse model
of AD (3xTgAD) can be beneﬁcial.
Wang et al. in 2010 showed that the decreased neurogenesis in
the subgranular zone of the hippocampal dentate gyrus in these
AD mice was reversed by one allopregnanolone injection (10 mg/kg
s.c.) [66]. In the same study it was shown that the memory of a
trace eye-blink conditioning returned to normal in the 3xTgAD
mice three weeks after a single allopregnanolone treatment. The
reported cortex allopregnanolone concentration was high, i.e.
0.5 mmol/kg (159 ng/g) at half an hour [33,34] and still 47 nmol/kg
(15 ng/g) 24 h after the treatment [66]. In further studies it was
shown that for maximal efﬁcacy treatment with allopregnanolone
(10 mg/kg s.c.) should be once a week to promote neurogenesis,
survival of the newly generated cells, and reduction in beta-
amyloid [19]. It was in this study also shown that an intense
treatment, i.e. three times a week for three month reduced
neurogenesis in the AD mice. Singh et al. in 2011 followed up with a
study showing that allopregnanolone (10 mg/kg s.c.) effectively
inﬂuenced trace eye-blink conditioning in 6 and 9 month old
3xTgAD mice, but not in the 12 month old AD mice. Contrary, in
15 month old non-transgenic mice decreased learning of trace eye-
blink conditioning and decreased neurogenesis was rescued by one
allopregnanolone treatment [60].
To induce these positive effects by allopregnanolone the
temporal exposure is very different to that by Bengtsson et al.
that showed allopregnanolone to negatively affect the AD disease
progression in two different AD mice models (APPSwePS1DE9 and
APPSwe/Arc [10,9]). In those studies there was for several month a
constant exposure to a low allopregnanolone concentration, i.e.
15 nmol/kg in the hippocampus. As described above, to induce
neurogenesis the optimal administration schedule is to give
allopregnanolone with one week intervals and at therapeutic doses
the peak brain allopregnanolone concentrations is at least
0.5 mmol/kg that then quickly returns to basal levels [34].
Interestingly, allopregnanolone treatment is in progress as a
therapeutic approach to regenerate the neurogenic capacity of the
brain (ClinicalTrials.gov Identiﬁer:NCT02221622).
There are also other examples where positive effects of
allopregnanolone treatment have been shown in different animal
models e.g. anxiolytic activity and decrease in epileptic dischargesanolone Allopregnanolone and 
isoallopregnanolone
AllopregnanoloneC
C while there is no interference when allopregnanolone has not been added. Traces
 condition and with applied isoallopregnanolone are interchangeable, i.e. there is no
lone prolongation of the sIPSC decay time, (C) Isoallopregnanolone antagonize the
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treatment effects of allopregnanolone [14,44,15,28], and it is out of
the scope of this review concerning GAMSA to go through these
studies.
4. GABAA receptor modulating steroid antagonists (GAMSA)—in
vitro studies
GAMSAs are antagonists to the positive GABAA receptor-modulat-
ing steroids. An example is the endogenous steroid isoallopregnano-
lone (3b-hydroxy-5a-pregnan-20-one, Fig 1), an epimer to
allopregnanolone, structurally differing only in the orientation of
the hydroxyl group at carbon 3 of the steroid A-ring. Several other 3b-
hydroxy-steroids are also functional GAMSAs [68,61].
The antagonistic effect of isoallopregnanolone has been studied
using several techniques, both in vitro and in vivo. Voltage-clamp
studies of recombinant GABAA receptors containing rat a1-
subunits expressed in Xenopus oocytes have demonstrated that
isoallopregnanolone inhibits the receptors’ potentiation by allo-
pregnanolone [68]. Similarly, local application of isoallopregna-
nolone to the pyramidal cell layer of hippocampal slices from rats
dose-dependently antagonizes allopregnanolone-mediated inhi-
bition of the CA1 pyramidal neuronal population spike evoked by
electrical stimulation of the Schaffer collaterals [67,69].
Isoallopregnanolone antagonism was ﬁrst shown to be speciﬁc
for steroids that positively modulate GABAA receptors by demon-
strations that it antagonizes allopregnanolone-enhanced chloride
ion uptake by isolated rat brain cortical microsacs in the presence of
GABA, but not when the chloride ion uptake is driven solely by GABA
[43]. No antagonism was detected when the benzodiazepine
ﬂunitrazepam orthebarbituratepentobarbitalwereusedto enhance
the chloride ion uptake either. More speciﬁc studies (Fig. 3A) have
shown that isoallopregnanolone does not affect the sIPSC in acutely
isolated neurons from the medial preoptic nucleus in the absence of
allopregnanolone, i.e. when the current is induced solely by
spontaneous release of GABA from presynaptic adhering nerve
terminals. However, isoallopregnanolone abolishes prolongation of
the sIPSC induced by allopregnanolone application (Fig. 3B and C,
modiﬁed from Strömberg et al.) [61].
Other examples of GAMSA are UC1011 (3b-20b-dihydroxy-5a-
pregnane) that in studies with isolated microsacs antagonizes the
allopregnanolone potentiation of chloride ion uptake in the
presence of GABA in both hippocampal and cortical microsacs
[65], and GR3027 that antagonizes THDOC but not GABA at both
human a1b2g2 and a5b3g2 GABAA receptors expressed in HEK-
293 cells [37]. Finally, 17PA ((3a5a)-17-phenylandrost-16-en-3-ol)
selectively antagonizes the 5a-reduced neurosteroid potentiation
of the GABA response from rat a1b2g2 GABAA receptors expressed
in Xenopus oocytes [48]. This means that 17PA at the GABAA
receptors antagonizes the effects of allopregnanolone, but not that
of pregnanolone that is the 5b isomer of allopregnanolone. 17PA
also antagonizes 5a-reduced steroids at native GABAA receptors in
isolated rat hippocampal neurons and cortical synaptoneurosomes
[48,39].
5. GABAA receptor modulating steroid antagonists (GAMSA)—in
vivo studies
5.1. The GAMSA UC1011 is an inhibitor of allopregnanolone-decreased
learning in rat
A direct evidence that GAMSAs may effectively antagonize
neurosteroid-induced learning impairment is the demonstration
by [65] that UC1011 antagonizes the impairment of rats’
performance in the Morris water maze test induced by acute
pre-administration of allopregnanolone (Fig. 2) [65]. Rats givenallopregnanolone alone did not learn the platform’s location, but
the latency of rats given both allopregnanolone and
UC1011 decreased during practice, and their performance was
signiﬁcantly enhanced by the GAMSA treatment during days 3–6 of
the test. UC1011 alone had no effect on the rats’ learning.
In the Morris water maze test a hippocampal-dependent
memory is formed and allopregnanolone probably affects learning
and memory via hippocampal GABAA receptors, while
UC1011 probably enhances learning in allopregnanolone-treated
rats by antagonistic effects within the hippocampus.
5.2. The GAMSA GR3027 restores learning and motor coordination in
rats with hepatic encephalopathy
Recently this year it was shown that chronic daily treatment
with GR3027 to rats with hepatic encephalopathy induced by
chronic ammonia feeding or by portacaval shunts restores affected
behaviors in the HE rats [37]. In both HE models an impaired motor
coordination was recognized in the beam walking test, and
GR3027 restored the motor function to that of controls. Also, in
the Morris water maze test memory was signiﬁcantly decreased in
the HE rats, and treatment with GR3027 restored the impaired
memory. Further, working memory was studied with the radial
arm maze and in the test GR3027 restored the increased number of
working errors found in the vehicle treated HE rats. At the same
time the blood ammonia concentration was unaffected by
GR3027 exposure.
The only known mechanism of GR3027 is to antagonize
allopregnanolone and THDOC at the GABAA receptor. This point
to the possibility that increased concentrations of positive GABAA
receptor-modulating steroids are the cause, or at least part of the
cause, of the disrupted CNS function seen in hepatic encephalopa-
thy.
Of importance is also that the long term daily treatment with
the GAMSA GR3027 did not negatively affect the rats in any sense,
i.e. there were no toxicity signs.
5.3. In vivo antagonism by isoallopregnanolone
Isoallopregnanolone is also a functional GAMSA in vivo, in both
rats [6] and humans [11], but no studies of its effects on learning or
memory have been published.
A study of a threshold model of deep allopregnanolone-induced
anesthesia in rat showed that when isoallopregnanolone was given
either before or together with allopregnanolone the dose of
allopregnanolone needed to reach the threshold increased. Thus,
isoallopregnanolone antagonizes the anesthetic action of allopreg-
nanolone in rats [6].
Intriguingly, allopregnanolone induces anxiety in pubertal
female mice, but it is anxiolytic in pre-pubertal mice [59]. Similar
changes in anxiety levels have been indicated by the time rats have
spent in the open arms of an elevated plus maze following
induction of endogenous allopregnanolone production by preced-
ing restraint stress or allopregnanolone injection. However, pre-
administration of the GAMSA isoallopregnanolone inhibited both
the stress-induced anxiety in pubertal female mice and stress-
induced anxiolytic effect of allopregnanolone observed in pre-
pubertal female mice. Blocking stress-induced allopregnanolone
production by ﬁnasteride had the same effects. These ﬁndings
clearly indicate that isoallopregnanolone can antagonize both
anxiety and anxiolysis induced by endogenous allopregnanolone.
In humans allopregnanolone dose-dependently decreases the
maximal velocity of saccadic eye movement (SEV) and increases
sedation [63]. SEV has been validated as a biomarker for effects of
GABAA receptor modulators, especially benzodiazepines [23].
Administration of isoallopregnanolone together with
M. Johansson et al. / Journal of Steroid Biochemistry & Molecular Biology 160 (2016) 98–105 103allopregnanolone reportedly diminishes the change in SEV and
self-rated sedation, and the effects indicate that the antagonism is
probably non-competitive [11]. Also, in a recent phase I/II clinical
trial with isoallopregnanolone to treat premenstrual dysphoric
disorder no adverse signs were noted by the GAMSA treatment
[13].
5.4. In vivo antagonism by 17PA
In tadpoles 17PA antagonizes 5a-reduced steroid-induced
anesthesia, while anesthesia induced by a 5b-reduced steroid
was unaffected [48]. Also in rats sedation/hypnosis induced by
allopregnanolone was antagonized by 17PA given intracerebro-
ventricular [39]. This was analyzed by studies of the righting reﬂex,
i.e. the ability of the rat to right when placed in a supine position.
5a-reduced steroids induce a loss of the righting reﬂex and when
17PA was present higher doses of the steroid were needed to lose
the reﬂex. Also, with 17PA pretreatment the total sleep time after
allopregnanolone was attenuated.
In rats allopregnanolone got a spinal analgesic action, and a
dose-dependent analgesia has been measured by thermal thresh-
old [62]. In this situation intrathecal 17PA completely prevented
the analgesic allopregnanolone effect both on the normal and the
inﬂammation evoked hyperalgesic paw [62].
6. Not all antagonists at GABAA receptors antagonize
allopregnanolone and THDOC
Several studies have found that the benzodiazepine antagonist
ﬂumazenil does not antagonize steroids that positively modulate
the GABAA receptor. For example, it has no effect on allopreg-
nanolone’s potentiation of the GABAA receptor current according
to patch-clamp studies of hippocampal cultures [3], and in vivo it
does not antagonize allopregnanolone-induced hyperphagia in
rats [56], or pregnanolone discriminative stimulus effects in
Rhesus monkeys [26]. Similarly, in humans ﬂumazenil does not
antagonize the reduction in saccadic eye velocity induced by
allopregnanolone [5]. However, at least one study has reported an
antagonistic effect: that ﬂumazenil antagonizes allopregnanolone-
decreased probe-burying in female Wistar rats, and thus appar-
ently counters allopregnanolone’s anxiolytic effect in them [25].
The ethanol antidote Ro15-4513 is a weak benzodiazepine
antagonist that in vivo does not antagonize the contextual learning
disruption caused by allopregnanolone in C57Bl6 mice [22].
However, in vitro the allopregnanolone potentiation of the GABAA
receptor current has been shown to be antagonized [3].
In contrast, GABAA receptor antagonists directed against the
GABA site, like bicuculline, or chloride channel blockers such as
picrotoxin, or the GABAA receptor negative allosteric modulator
pregnenolone sulfate block both the effect of GABA and
allopregnanolone/THDOC potentiation of the receptor [45,42,29].
Use of such substances in vivo is dangerous as blockage of the GABA
effect at the GABAA receptor leads to over-excitation with
induction of seizures. This highlights the need to use GAMSAs,
i.e. speciﬁc neurosteroid antagonists that do not affect GABA
responses, when attempting to inhibit cognitive deﬁcits or other
adverse conditions mediated by allopregnanolone, for safety
reasons.
7. Conclusion
The purpose of this review article was to describe a novel class
of compounds as potential therapeutic agents to prevent the
actions of neurosteroids on the GABAA receptor.
Neurosteroids such as allopregnanolone and THDOC are
positive allosteric modulators of GABAA receptors with pleiotropicphysiological manifestations. For example, pharmacologic treat-
ment with allopregnanolone can be beneﬁcial to block Status
Epilepticus and with special treatment schedules neurogenesis can
be induced in rodents. However, allopregnanolone and THDOC also
impair cognitive functions in rodents and in humans.
Changes in the levels of neurosteroids have also been associated
with clinical symptoms. For example increased brain levels of
allopregnanolone offer a cogent explanation for the notion of
‘increased GABAergic tone’ in hepatic encephalopathy (HE) and the
increased GABAergic tone is a credible cause of the cognitive
symptoms that appears in HE. In premenstrual dysphoric disorder
(PMDD) plasma allopregnanolone levels are increased in the luteal
phase of the menstrual cycle, and in the same time period the
PMDD symptoms are present.
Pharmacological approaches using agents that inhibit the
positive modulatory action of GABA-steroids on the GABAA
receptor could therefore offer new therapeutic tools for the
management and treatment of HE in patients with liver disease
and PMDD in women.
GAMSA is a novel class of pharmacologically active compounds
that are antagonists to positive GABAA receptor modulating
steroids. GAMSA antagonizes the neurosteroid-potentiation of
the GABA mediated activation of the receptor without affecting the
GABA induced chloride ﬂux through the receptor. In conclusion,
GAMSA offers a novel pharmacological approach by antagonizing
the enhanced GABAergic tone caused by increased levels of GABAA
receptor modulating steroids and with a favorable side effect
proﬁle supported by preclinical and clinical use.
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